SSTR-positive neuroendocrine tumors: peptide receptor radionuclide therapy

被引：0
作者：
不详
机构：
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S66 / S69
页数：4
相关论文
共 18 条
[1]   Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours [J].
Adant, Samuel ;
Shah, Girish M. ;
Beauregard, Jean-Mathieu .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) :907-921
[2]   [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study [J].
Baum, Richard P. ;
Kluge, Andreas W. ;
Kulkarni, Harshad ;
Schorr-Neufing, Ulrike ;
Niepsch, Karin ;
Bitterlich, Norman ;
van Echteld, Cees J. A. .
THERANOSTICS, 2016, 6 (04) :501-510
[3]   Targeted a-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial [J].
Delpassand, Ebrahim S. ;
Tworowska, Izabela ;
Esfandiari, Rouzbeh ;
Torgue, Julien ;
Hurt, Jason ;
Shafie, Afshin ;
Nunez, Rodolfo .
JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (09) :1326-1333
[4]  
Delpassand ES, 2022, NANETS
[5]  
Guenter R, 2022, NANETS
[6]  
Halfdanarson TR, 2022, NANETS
[7]  
Hope T, 2022, NANETS
[8]   NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE [J].
Hope, Thomas A. ;
Abbott, Amanda ;
Colucci, Karen ;
Bushnell, David L. ;
Gardner, Linda ;
Graham, William S. ;
Lindsay, Sheila ;
Metz, David C. ;
Pryma, Daniel A. ;
Stabin, Michael G. ;
Strosberg, Jonathan R. .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) :937-943
[9]   Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review [J].
Koh, Thuan Tzen ;
Bezak, Eva ;
Chan, David ;
Cehic, Gabrielle .
WORLD JOURNAL OF NUCLEAR MEDICINE, 2021, 20 (04) :329-335
[10]  
Madigan JP, 2022, NANETS
12